While AHR agonism with FICZ improved MS tolDC tolerogenic features, its clinical use in MS is challenging owing to its instability, rapid pharmacokinetics (56), and induction of Th17 cells, which drive MS pathogenesis (57). The gene discussed is AHR; the disease is myeloid sarcoma.